

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. GMB 0831-0831
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Application Number</i>	10/511,832
		<i>Filing Date</i>	10/19/2004
		<i>First Named Inventor</i>	Susan M. Freier
		<i>Art Unit</i>	To Be Determined
		<i>Examiner Name</i>	To Be Determined
Sheet	1	of	2
		<i>Attorney Docket Number</i>	RTS-0428USA

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ⁴Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

WFO Standard 31, if possible. Applicants to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>(Use as many sheets as necessary)</i>	<i>Application Number</i>	10/511,832
		<i>Filing Date</i>	10/19/2004	
		<i>First Named Inventor</i>	Susan M. Freier	
		<i>Art Unit</i>	To Be Determined	
		<i>Examiner Name</i>	To Be Determined	
Sheet	2	of	2	Attorney Docket Number
RTS-0428USA				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	AF	ALBERTS, P. et al., "Selective Inhibition of 11 β -Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains," <i>Endocrin.</i> (2003) 144(11):4755-4762.		
	AG	BERGER, J. et al., "Peroxisome Proliferator-activated Receptor-g Ligands Inhibit Adipocyte 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity," <i>J. Biol. Chem.</i> (2001) 276(16):12629-12635.		
	AH	HATAKEYAMA, H. et al., "11 β -Hydroxysteroid Dehydrogenase Activities in Cultured Human Vascular Smooth Muscle Cells," <i>Front. Sci. Ser.</i> (2000) 29:173-174.		
	AI	KOTELEVTSOV, Y. et al., "11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress," <i>Proc. Natl. Acad. Sci. USA</i> (1997) 94:14924-14929, 1997.		
	AJ	LINK, J. T., "Pharmacological regulation of hepatic glucose production," <i>Curr. Opin. Invest. Drugs</i> (2003) 4(4):421-429.		
	AK	MACKENZIE, M. A. et al., "The Influence of Glycyrrhetic Acid on Plasma Cortisol and Cortisone in Healthy Young Volunteers," <i>J. Clin. Endocrinol. Metab.</i> (1990) 70(6):1637-1643.		
	AL	MASUZAKI, H. et al., "A Transgenic Model of Visceral Obesity and the Metabolic Syndrome," <i>Science</i> (2001) 294:2166-2170.		
	AM	RASK, E. et al., "Tissue-specific dysregulation of cortisol metabolism in human obesity," <i>J. Clin. Endocrinol. Metab.</i> (2001) 86(3):1418-1421.		
	AN	SOUNESS, G. W. et al., "11 β -Hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism," <i>Steroids</i> (2002) 67:195-201.		
	AO	STEWART, P. M. et al., "Mineralocorticoid activity of carbinoxolone: contrasting effects of carbinoxolone and liquorice on 11 β -hydroxysteroid dehydrogenase activity in man," <i>Clin. Sci.</i> (1990) 78:49-54.		

3/16/10

Examiner Signature	/Sean McGarry/	Date Considered	03/26/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.